Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 10/20 | 0.55 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | KIF23 | Q02241 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 7/20 | 0.41 |
| ▸ | PDE6D | O43924 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4320506 | 1.00 | KIF11 (0.55) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL4320508 | 1.00 | KIF11 (0.55) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL4326718 | 0.89 | KIF11 (0.61) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL4322824 | 0.89 | KIF11 (0.57) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL4326723 | 0.89 | KIF11 (0.61) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL4326716 | 0.89 | KIF11 (0.61) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL4316742 | 0.89 | KIF11 (0.57) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL4322822 | 0.89 | KIF11 (0.57) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL4282121 | 0.89 | KIF11 (0.70) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL5062366 | 0.87 | KIF11 (0.56) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7632839-B2 | Mitotic kinesin inhibitors | MERCK & CO. INC. (US) | 2009-12-15 | — | — | US | disclosed |
| US-20080139586-A1 | Mitotic Kinesin Inhibitors | MERCK SHARP & DOHME CORP. | 2008-06-12 | — | — | US | disclosed |
| EP-1855664-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006078575-A2 | FLUORINATED AMINOALKYL-4-OXO-3,4-DIHYDROPYRIDO[3,4- D] PYRIMIDINES AS INHIBITORS OF MITOTIC KINESINS | MERCK & CO., INC. (US) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139586-A1 | Mitotic Kinesin Inhibitors | KIF5B, KIF2C, KIFC1 | KIF11 8/4885MAP1LC3B 148/4885CYP3A4 4765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.